BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11932909)

  • 1. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.
    Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M
    Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
    Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
    J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.
    Cho JY; Kim JH; Lee YH; Chung KY; Kim SK; Gong SJ; You NC; Chung HC; Roh JK; Kim BS
    Cancer; 1997 Feb; 79(3):462-7. PubMed ID: 9028355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
    Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
    Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
    Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
    Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
    Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
    J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
    Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M
    Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
    Zhang G; Sun Y; Wang M
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K-ras gene mutations in non-small cell lung cancer in Japanese.
    Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
    Oncol Rep; 2001; 8(4):889-92. PubMed ID: 11410804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
    Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
    Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
    Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
    J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.